Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

773 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of the EMPYREAN study.
Motoki H, Masuda I, Yasuno S, Oba K, Shoin W, Usami S, Saito Y, Waki M, Komatsu M, Ueshima K, Nakagawa Y, Son C, Yonemitsu S, Hiramitsu S, Konda M, Onishi K, Kuwahara K. Motoki H, et al. Among authors: son c. ESC Heart Fail. 2020 Oct;7(5):3134-3141. doi: 10.1002/ehf2.12825. Epub 2020 Jun 23. ESC Heart Fail. 2020. PMID: 32578353 Free PMC article. Clinical Trial.
Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial.
Son C, Kasahara M, Tanaka T, Satoh-Asahara N, Kusakabe T, Nishimura K, Miyamoto Y, Kasama S, Hosoda K. Son C, et al. Diabetes Ther. 2020 Jan;11(1):347-358. doi: 10.1007/s13300-019-00717-9. Epub 2019 Nov 1. Diabetes Ther. 2020. PMID: 31677134 Free PMC article.
Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
Son C, Makino H, Kasahara M, Tanaka T, Nishimura K, Taneda S, Nishimura T, Kasama S, Ogawa Y, Miyamoto Y, Hosoda K. Son C, et al. Diabetes Res Clin Pract. 2021 Oct;180:109037. doi: 10.1016/j.diabres.2021.109037. Epub 2021 Sep 2. Diabetes Res Clin Pract. 2021. PMID: 34481910 Free article. Clinical Trial.
Addition of low-dose liraglutide to insulin therapy is useful for glycaemic control during the peri-operative period: effect of glucagon-like peptide-1 receptor agonist therapy on glycaemic control in patients undergoing cardiac surgery (GLOLIA study).
Makino H, Tanaka A, Asakura K, Koezuka R, Tochiya M, Ohata Y, Tamanaha T, Son C, Shimabara Y, Fujita T, Miyamoto Y, Kobayashi J, Hosoda K. Makino H, et al. Among authors: son c. Diabet Med. 2019 Dec;36(12):1621-1628. doi: 10.1111/dme.14084. Epub 2019 Aug 2. Diabet Med. 2019. PMID: 31335979 Clinical Trial.
The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL).
Kataoka Y, Hosoda K, Makino H, Matsubara M, Matsuo M, Ohata Y, Koezuka R, Tamanaha T, Tomita T, Honda-Kohmo K, Noguchi M, Son C, Nishimura K, Asaumi Y, Miyamoto Y, Noguchi T, Yasuda S. Kataoka Y, et al. Among authors: son c. Cardiovasc Diagn Ther. 2019 Oct;9(5):431-438. doi: 10.21037/cdt.2019.09.02. Cardiovasc Diagn Ther. 2019. PMID: 31737515 Free PMC article.
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design.
Fujiki S, Iijima K, Okabe M, Niwano S, Tsujita K, Naito S, Ando K, Kusano K, Kato R, Nitta J, Miura T, Mitsuhashi T, Kario K, Kondo Y, Ieda M, Hagiwara N, Murohara T, Takahashi K, Tomita H, Takeishi Y, Anzai T, Shimizu W, Watanabe M, Morino Y, Kato T, Tada H, Nakagawa Y, Yano M, Maemura K, Kimura T, Yoshida H, Ota K, Tanaka T, Kitamura N, Node K, Aizawa Y, Shimizu I, Izumi D, Ozaki K, Minamino T; EMPA-ICD investigators. Fujiki S, et al. Diabetes Ther. 2020 Nov;11(11):2739-2755. doi: 10.1007/s13300-020-00924-9. Epub 2020 Sep 23. Diabetes Ther. 2020. PMID: 32968947 Free PMC article.
A Prospective Longitudinal Study on the Relationship Between Glucose Fluctuation and Cognitive Function in Type 2 Diabetes: PROPOSAL Study Protocol.
Matsubara M, Makino H, Washida K, Matsuo M, Koezuka R, Ohata Y, Tamanaha T, Honda-Kohmo K, Noguchi M, Tomita T, Son C, Nakai M, Nishimura K, Miyamoto Y, Ihara M, Hosoda K. Matsubara M, et al. Among authors: son c. Diabetes Ther. 2020 Nov;11(11):2729-2737. doi: 10.1007/s13300-020-00916-9. Epub 2020 Sep 5. Diabetes Ther. 2020. PMID: 32889699 Free PMC article.
773 results